COMPANY
Livionex Pharma
Timeline
- Trial start Phase 1/Phase 2: The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Catarac source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06365762 | The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract | Phase 1/Phase 2 | Completed | Jan 1, 2006 | Dec 31, 2006 (actual) |
NIH awards 1
- NIH award 1R43AR062419-01 FY2012: $297,319 awarded for that fiscal year; activity R43 (SBIR); PI GIN, JERRY; recipient as written: LIVIONEX, INC., LOS GATOS, CA. Localized Metal Modulation as a First Line Treatment o source ↗